Trial · NCT03534180
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
NCT03534180, Phase 2, Completed, City of Hope Medical Center; results first posted 2023-06-22
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma. Trials, record NCT03534180. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03534180
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
- NCT number
- NCT03534180
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- City of Hope Medical Center
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Romidepsin, Venetoclax
- First posted
- 2018-05-23
- Last updated
- 2026-10-29
- Results first posted
- 2023-06-22
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patients With Grade 3 or Above Toxicities | Up to 30 days post-treatment, an average of 4 months. | Graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0. During the first 2 cycles, all grades of toxicity will be collected. After cycle 2, only the highest grade of any toxicity will be collected for each cycle during protocol treatment and for the period of safety follow-up after end of treatment. |
| Secondary | Overall Survival at 100 Days | From the start of study treatment up to 100 days | Overall survival (OS) was measured from start of the study treatment to death from any cause. OS to be estimated using the product-limit method of Kaplan- Meier with the Greenwood estimator of standard error. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patients With Grade 3 or Above Toxicities | Up to 30 days post-treatment, an average of 4 months. | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Survival at 100 Days | From the start of study treatment up to 100 days | percent probability | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patients With Grade 3 or Above Toxicities | Treatment (Venetoclax, Romidepsin) | 9 | Participants | ||
| Overall Survival at 100 Days | Treatment (Venetoclax, Romidepsin) | 63 | 95% Confidence Interval 23 to 86 | percent probability |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Venetoclax, Romidepsin) | 9 | |
| Overall Study | COMPLETED | Treatment (Venetoclax, Romidepsin) | 8 | |
| Overall Study | NOT COMPLETED | Treatment (Venetoclax, Romidepsin) | 1 |
Source ClinicalTrials.gov
Adverse events108
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Venetoclax, Romidepsin) | 7 | 9 | 40 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Treatment (Venetoclax, Romidepsin) | 1 | 9 | 3 |
| other | Leukocytosis | Blood and lymphatic system disorders | Treatment (Venetoclax, Romidepsin) | 2 | 9 | 4 |
| other | Thrombotic thrombocytopenic purpura | Blood and lymphatic system disorders | Treatment (Venetoclax, Romidepsin) | 1 | 9 | 1 |
| other | pancytopenia | Blood and lymphatic system disorders | Treatment (Venetoclax, Romidepsin) | 1 | 9 | 1 |
| other | pulmonary embolism | Blood and lymphatic system disorders | Treatment (Venetoclax, Romidepsin) | 1 | 9 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Treatment (Venetoclax, Romidepsin) | 3 | 9 | 6 |
| other | Blurred vision | Eye disorders | Treatment (Venetoclax, Romidepsin) | 1 | 9 | 1 |
| other | Periorbital edema | Eye disorders | Treatment (Venetoclax, Romidepsin) | 2 | 9 | 2 |
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Venetoclax, Romidepsin) | 1 | 9 | 1 |
1 to 10 of 108Source ClinicalTrials.gov
See all 108 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Venetoclax, Romidepsin) | 6 | 9 |
| Total, other adverse events | Treatment (Venetoclax, Romidepsin) | 9 | 9 |
| Total, serious adverse events | Treatment (Venetoclax, Romidepsin) | 5 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA033572 | Cancer Center Support Grant | CARPTEN, JOHN D. | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03534180
GET https://conductscience.org/api/trials/v1/NCT03534180/events?page=2